| Literature DB >> 25186948 |
Jiangbin Ye1, Jing Fan2, Sriram Venneti1, Ying-Wooi Wan3, Bruce R Pawel4, Ji Zhang1, Lydia W S Finley1, Chao Lu1, Tullia Lindsten1, Justin R Cross5, Guoliang Qing6, Zhandong Liu7, M Celeste Simon8, Joshua D Rabinowitz2, Craig B Thompson9.
Abstract
UNLABELLED: The de novo synthesis of the nonessential amino acid serine is often upregulated in cancer. In this study, we demonstrate that the serine catabolic enzyme, mitochondrial serine hydroxymethyltransferase (SHMT2), is induced when MYC-transformed cells are subjected to hypoxia. In mitochondria, SHMT2 can initiate the degradation of serine to CO2 and NH4+, resulting in net production of NADPH from NADP+. Knockdown of SHMT2 in MYC-dependent cells reduced cellular NADPH:NADP+ ratio, increased cellular reactive oxygen species, and triggered hypoxia-induced cell death. In vivo, SHMT2 suppression led to impaired tumor growth. In MYC-amplified neuroblastoma patient samples, there was a significant correlation between SHMT2 and hypoxia-inducible factor-1 α (HIF1α), and SHMT2 expression correlated with unfavorable patient prognosis. Together, these data demonstrate that mitochondrial serine catabolism supports tumor growth by maintaining mitochondrial redox balance and cell survival. SIGNIFICANCE: In this study, we demonstrate that the mitochondrial enzyme SHMT2 is induced upon hypoxic stress and is critical for maintaining NADPH production and redox balance to support tumor cell survival and growth. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25186948 PMCID: PMC4258153 DOI: 10.1158/2159-8290.CD-14-0250
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397